Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study

Despite reducing progression and promoting regression of coronary atherosclerosis, statin therapy does not fully address residual cardiovascular (CV) risk. High‐purity eicosapentaenoic acid (EPA) added to a statin has been shown to reduce CV events and induce regression of coronary atherosclerosis i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cardiol
Main Authors: Budoff, Matthew, Brent Muhlestein, J., Le, Viet T., May, Heidi T., Roy, Sion, Nelson, John R.
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley Periodicals, Inc. 2018
Assuntos:
Trial Designs
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838559/
https://ncbi.nlm.nih.gov/pubmed/29365351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22856
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados